WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of the Endocrine and Neuroendocrine Tumours. 5th ed. Lyon: IARC Press; 2022.
[2]
Lloyd RV, Osamura RY, Klöppel G, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: IARC; 2017.
[3]
Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Endocr Pathol. 2018;29(4):289-297.
[4]
Fishbein L, Merrill S, Fraker DL, et al. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be referred for genetic testing. Ann Surg Oncol. 2019;26(5):1534-1540.
[5]
Jochmanova I, Pacak K. Pheochromocytoma: the first metabolic endocrine disorder. J Clin Endocrinol Metab. 2018;103(3):803-804.
[6]
Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy in patients with paragangliomas. Cancer. 2019;125(7):1126-1135.
[7]
Hescot S, Curras-Freixes M, Vezzosi D, et al. Prognostic value of SDHB mutations in paraganglioma patients. J Clin Endocrinol Metab. 2020;105(3):dgz099.
[8]
Kalerski P, Zawadzka K, Lewczuk A, et al. Genetics of pheochromocytoma and paraganglioma. Endokrynol Pol. 2021;72(4):365-376.
[9]
Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol. 2017;28(4):285-290.
[10]
Brenner DR, O'Sullivan DE, Hammad R, et al. Incidence and survival outcomes for paragangliomas in the United States. J Neurooncol. 2021;154(2):285-294.